U.S. Markets close in 3 hrs 7 mins

Affymetrix gets FDA approval for CytoScan Dx Assay

The U.S. FDA authorized for marketing the Affymetrix CytoScan Dx Assay, which can detect chromosomal variations that may be responsible for a child's developmental delay or intellectual disability. Based on a blood sample, the test can analyze the entire genome at one time and detect large and small chromosomal changes.